Considering Uniqure NV (QURE) Stock? Read the AMT-130 Message

Uniqure NV (NASDAQ:QURE) is one of the best gene therapy stocks to buy in 2026. Uniqure shares have gained 60% over the past month and more than doubled over the past year. The Street believes the stock’s rally isn’t done yet and anticipates at least a 40% gain over the next 12 months.

Considering Uniqure NV (QURE) Stock? Read the AMT-130 Message

On April 30, Uniqure announced plans to apply for regulatory approval of its product candidate AMT-130 in the UK. AMT-130 is a gene therapy targeting Huntington’s disease. Uniqure plans to file for AMT-130’s approval with the UK regulator in Q3 2026.

The UK filing will be based on the data from the ongoing Phase 1/2 clinical trials of AMT-130 in the US and Europe. When trial data were analyzed at the three-year mark, the results showed that patients treated with the high dose of AMT-130 showed a 75% slowing of Huntington’s disease progression.

Uniqure has discussed the data package and manufacturing requirements with the UK regulator to support the AMT-130 application. Uniqure CEO Matt Kapusta said that they received constructive feedback from the UK regulator as they work toward securing marketing approval for AMT-130.

The company is also eying AMT-130 approval in the US. It plans to meet the FDA in Q2 2026 to discuss a potential Phase 3 trial of AMT-130, which could pave the way for approval of Huntington’s disease gene therapy in the US.

Uniqure NV (NASDAQ:QURE) is a Dutch biotech company founded in 1998 and based in Amsterdam, Netherlands. It develops gene therapies for rare and severe diseases. Uniqure is an industry leader, as its Glybera product became the first approved gene therapy in the Western world.

While we acknowledge the risk and potential of QURE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than QURE and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 8 Best Middle East and Africa Stocks to Buy According to Hedge Funds and 10 Undervalued Aerospace and Defense Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1